<DOC>
	<DOCNO>NCT01667458</DOCNO>
	<brief_summary>This observational study evaluate presence evolution fatigue treatment RoActemra/Actemra ( tocilizumab ) patient moderate severe rheumatoid arthritis inadequate response least two DMARDs ( one methotrexate ) anti-TNF treatment . Patients initiated treatment RoActemra/Actemra ( 8 mg/kg intravenously every 4 week ) without methotrexate follow 4 month .</brief_summary>
	<brief_title>An Observational Study Fatigue Patients With Rheumatoid Arthritis Treated With RoActemra/Actemra ( Tocilizumab )</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Fatigue</mesh_term>
	<criteria>Adult patient , &gt; /= 18 year age Moderate severe active rheumatoid arthritis , define DAS28 &gt; /= 3.7 Inadequate clinical response current treatment &gt; /= 2 nonbiologic DMARDs , 1 methotrexate optimally administer &gt; /= 3 month , inadequate clinical response antiTNF therapy Eligible RoActemra/Actemra treatment daily clinical practice Absence evolutive tuberculosis ( TB ) Hypersensitivity tocilizumab excipients Active , severe infection Pregnant lactate woman Participation interventional study Patients major depression</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>